CHEBI:49668 - gefitinib

Main ChEBI Ontology Automatic Xrefs Reactions Pathways Models
ChEBI Name gefitinib
ChEBI ID CHEBI:49668
Definition A member of the class of quinazolines that is quinazoline which is substituted by a (3-chloro-4-fluorophenyl)nitrilo group, 3-(morpholin-4-yl)propoxy group and a methoxy group at positions 4,6 and 7, respectively. An EGFR kinase inhibitor used for the treatment of non-small cell lung cancer.
Stars This entity has been manually annotated by the ChEBI Team.
Secondary ChEBI IDs CHEBI:38917, CHEBI:49667
Supplier Information No supplier information found for this compound.
Download Molfile XML SDF
more structures >>
Wikipedia License
Gefitinib, sold under the brand name Iressa, is a medication used for certain breast, lung and other cancers. Gefitinib is an EGFR inhibitor, like erlotinib, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR, but resistances to gefitinib can arise through other mutations. It is marketed by AstraZeneca and Teva. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.
Read full article at Wikipedia
Formula C22H24ClFN4O3
Net Charge 0
Average Mass 446.910
Monoisotopic Mass 446.15210
InChI InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)
InChIKey XGALLCVXEZPNRQ-UHFFFAOYSA-N
SMILES C1=C(C(=CC=2C1=NC=NC2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4)OC
Roles Classification
Chemical Role(s): Bronsted base
A molecular entity capable of accepting a hydron from a donor (Bronsted acid).
(via organic amino compound )
Biological Role(s): epidermal growth factor receptor antagonist
An antagonist at the epidermal growth factor receptor.
Application(s): antineoplastic agent
A substance that inhibits or prevents the proliferation of neoplasms.
View more via ChEBI Ontology
ChEBI Ontology
Outgoing gefitinib (CHEBI:49668) has role antineoplastic agent (CHEBI:35610)
gefitinib (CHEBI:49668) has role epidermal growth factor receptor antagonist (CHEBI:74440)
gefitinib (CHEBI:49668) is a aromatic ether (CHEBI:35618)
gefitinib (CHEBI:49668) is a monochlorobenzenes (CHEBI:83403)
gefitinib (CHEBI:49668) is a monofluorobenzenes (CHEBI:83575)
gefitinib (CHEBI:49668) is a morpholines (CHEBI:38785)
gefitinib (CHEBI:49668) is a quinazolines (CHEBI:38530)
gefitinib (CHEBI:49668) is a secondary amino compound (CHEBI:50995)
gefitinib (CHEBI:49668) is a tertiary amino compound (CHEBI:50996)
Incoming linkable gefitinib analogue (CHEBI:39084) has functional parent gefitinib (CHEBI:49668)
IUPAC Name
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
INNs Sources
géfitinib WHO MedNet
gefitinib WHO MedNet
gefitinib WHO MedNet
gefitinibum WHO MedNet
Synonyms Sources
4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline ChemIDplus
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine ChemIDplus
ZD 1839 ChemIDplus
ZD-1839 DrugBank
ZD1839 DrugCentral
Brand Names Sources
Iressa ChemIDplus
Irressat ChemIDplus
Manual Xrefs Databases
1282 DrugCentral
D01977 KEGG DRUG
DB00317 DrugBank
Gefitinib Wikipedia
HMDB0014462 HMDB
IRE PDBeChem
LSM-1098 LINCS
View more database links
Registry Numbers Types Sources
184475-35-2 CAS Registry Number ChemIDplus
8949523 Reaxys Registry Number Reaxys
Citations Types Sources
14981586 PubMed citation Europe PMC
15068398 PubMed citation Europe PMC
20573926 PubMed citation Europe PMC
20949670 PubMed citation Europe PMC
27396387 PubMed citation Europe PMC
28968167 PubMed citation Europe PMC
29332330 PubMed citation Europe PMC
29493460 PubMed citation Europe PMC
29579334 PubMed citation Europe PMC
29668619 PubMed citation Europe PMC
30068310 PubMed citation Europe PMC
30069771 PubMed citation Europe PMC
30214852 PubMed citation Europe PMC
Last Modified
28 May 2019